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Abstract 
Background: Dyspnea is the most common presenting symptom in patients with 
acute heart failure (AHF). However, the minimal clinically important difference 
(MCID) to patients has not been well established.  
Methods: We performed a secondary analysis from URGENT Dyspnea, an 
observational, multi-center study of AHF patients enrolled within one hour of first 
physician assessment in the ED. Three scales were used to assess dyspnea: 1) 
10cm VAS 2) 5-point Likert, and 3) a 7-point Likert (both VAS and 5-point Likert 
were recorded in the upright and supine positions). Using the anchor-based 
method to determine the MCID, a one-category change in the 7-point Likert was 
used as the criterion standard (‘minimally improved or worse’).   
Results: Of the 776 patients enrolled, 491 had a final diagnosis of AHF with 
responses at both time points. A 10.5mm (SD 1.6 mm) change in VAS was the 
MCID for improvement in the upright position, and 14.5mm (SD 2.0mm) in the 
supine position. However, there was no MCID for worsening, as few patients 
reported worse dyspnea. There was also no significant MCID for the 5-point 
Likert scale. 
Conclusion:  A 10.5 mm change is the MCID for improvement in dyspnea over 6 
hours in ED patients with AHF.  
 
Key Words: dyspnea, acute heart failure, emergency department, MCID 
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Introduction 
Patient reported outcomes (PRO) are defined as ‘any report of the status 
of a patient’s health condition that comes directly from the patient, without 
interpretation of the patients response by anyone else.’1 As a measurement of 
patients’ experiences, PRO are key assessments in patient centered research.  
Dyspnea, or the sensation of breathlessness, is one of the most commonly 
measured PRO’s in acute heart failure (AHF) clinical trials. 
The sensation of difficulty breathing or shortness of breath compels 
patients with AHF to seek medical care.2,3 Early and persistent relief of dyspnea 
has been associated with improved outcomes.4-7 Although dyspnea is 
significantly improved after initial therapy,8 a substantial number of patients 
continue to have shortness of breath during hospitalization.4-6 As such, its relief is 
important to both patients and caregivers, especially with the current focus on 
patient centered outcomes.9   
As a subjective, patient reported symptom, how exactly to assess and 
measure dyspnea continues to be debated.9-11 While clinical trials now use a 
more standardized method of dyspnea assessment — formal training, 
standardized position, only after a period of rest7 — use of dyspnea as a clinical 
trial endpoint has fallen out of favor, in part due to the difficulty of demonstrating 
a significant difference between investigational agents and usual care.12,13 
However, as the predominant AHF symptom, relief from dyspnea is important to 
patients.  Similar to the measurement of pain, proper measurement of dyspnea in 
AHF is needed.9  
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The minimal clinically important difference (MCID) is the “smallest benefit 
of value to patients.” 14 As clinicians and patients may disagree on what is 
clinically meaningful, understanding patients’ perspective is critical for a patient 
centered outcome.  Knowing the MCID also informs clinical trial design, providing 
the minimal effect size. Despite the importance of dyspnea to patients and its 
near universal presence in AHF patients, the minimal clinically important 
difference (MCID) in dyspnea via various measurement scales has not been well 
studied.7 Thus, we performed a retrospective analysis of the URGENT-Dyspnea 
database to determine the MCID in dyspnea at 6 hours after initial management 
in patients with AHF presenting to the emergency department (ED). 
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Methods: 
Details regarding the URGENT Dyspnea (Ularitide Global Evaluation in 
Acute Decompensated Heart Failure) study design and main study results have 
been previously presented.8 Briefly, URGENT Dyspnea was a multi-center, 
prospective observational study that enrolled 776 patients from 17 countries 
involving 35 sites from January through August of 2007.  The primary objective 
was to determine changes in patient reported dyspnea over 6 hours, capturing 
patients shortly after ED presentation.  The study was IRB or Ethics Committee 
approved at every study site.   
 
Participants 
Patients were 18 years and older and enrolled within one hour of first 
physician contact.  Given the short time frame, patients with dyspnea presumed 
attributable to AHF were approached, consented, and then enrolled.  To best 
replicate ‘real-world’ conditions, inclusion and exclusion criteria were intentionally 
kept broad.  Treatment and management were directed by the patients’ clinical 
care team: there were no pre-specified protocols or treatment interventions.  
Demographic, clinical, and treatment data were collected per standardized case 
report form.  The site principal investigator, who had full access to all available 
clinical data, determined the final diagnosis of AHF.   
 
Dyspnea Assessment Instruments 
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At 6 hours after enrollment, patients were asked about the severity of their 
dyspnea.  They were asked to report via commonly used scales in AHF.  The 7-
point Likert scale: “Compared to how you felt when you first arrived, do you now 
feel your breathing is: Markedly worse, moderately worse, minimally worse, no 
change, minimally improved, moderately improved, markedly improved?”  A one-
category change of “minimally worse” or “minimally improved” was used as the 
criterion standard for the MCID in this study.  This standard was chosen based 
on previously published work in AHF and the MCID,15 which was based on prior 
work in the assessment of pain.15-17 
Two other scales were used to assess dyspnea at both time zero and 6 
hours later; a 5-point Likert scale (“I am not short of breath (SOB)”, “Mildly SOB”, 
“Moderately SOB”, “Severely SOB”, “Very Severely SOB”) and a 100mm VAS, 
with 0 as “I am not breathless at all” to 100mm as “I am the most breathless I 
have ever been.”  Per protocol, this 100mm line was divided into 10 equal one 
centimeter increments and scored accordingly.   
 
Outcome Measures 
 The main outcome measures were the change in visual analog scale 
(VAS) and 5-point Likert scale from baseline to 6-hour assessment relative to a 
1-category change response in the 7-point Likert scale (‘minimally worse’, ‘no 
change’, or ‘minimally better’).  
Both the 5-point Likert and VAS were measured in two positions to 
ascertain the effect of position on patient reported dyspnea.  Patients were 
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initially assessed in the upright position (seated, head of bed ≥ 60 degrees).  If 
patients reported “severely” or “very severely” by the 5-point Likert, the supine 
position was not assessed due to safety concerns.  For any other score, patients 
were placed in the supine position (head of bed ≤20 degrees) and after an 
equilibration period of 120seconds, both the 5-point Likert and 100mm VAS were 
repeated. 
 
Analysis Plan 
 We utilized the anchor based method to determine the MCID.14  To the 
best of our knowledge, the only other study to explore the MCID in AHF from the 
ED perspective also utilized the anchor based method.15  This method uses 
another measure of improvement – the 7-point Likert scale –  as the ‘anchor’ to 
associate change via another numerical scale.14 
 As we were not certain what the MCID would be, we did not pre-specify 
the effect size.  However, using conservative estimates, we have 80% power to 
detect a 10mm change in VAS corresponding to a 1 point minimal improvement 
by Likert, assuming a group size of 64 subjects and type 1 error controlled at 
0.05 (two-sided) 
 
Statistical Analysis 
Patients were divided into 3 groups based upon the 7-point Likert; 1) those 
reporting “No Change”, 2) those reporting “Minimally worse”, and 3) those 
reporting “Minimally improved”. Using this grouping, all other categories were 
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excluded.  To ascertain whether greater or lesser changes had value, additional 
analyses were performed by dividing the patients into three groups based on any 
reported improvement, any worsening, or no change in the 7-point Likert, thus 
using all eligible subjects.   
Baseline characteristics including frequencies and percentages for 
categorical variables and means and standard deviations for continuous 
variables, were calculated and compared between the groups using Fisher’s 
exact tests and one-way analysis of variance (ANOVA) models, as appropriate.  
 Change scores between responses at baseline and 6 hours on the 5-point 
Likert scale items and the VAS were calculated by subtracting the baseline value 
from the 6-hour value.  These change scores were categorized as improvement, 
worsening and no change.  Fisher’s exact tests were used to compare the 3 
groups by either definition on changes in the 5-point Likert scale and on the VAS 
in both the upright and supine positions.  Separate one-way analysis of variance 
(ANOVA) models were used to determine if there were any significant differences 
between the groups based on 6-hour changes for the 5-point Likert and VAS in 
both the upright and supine positions. For ease in interpretation, the change 
scores were reverse coded so that a positive score indicated improvement.  
Following a significant group effect, unadjusted pairwise comparisons were made 
between the groups.  Least square means and standard errors were reported 
from the models.  Kruskal Wallis tests were also used to look for overall group 
differences; as the results agreed with the ANOVA results, they were not 
presented. To determine concordance between the anchor scale and the 5-point 
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Likert and VAS, a kappa (κ) statistic was calculated and presented in the tables 
with 95% CI.  
 We did not control for multiple-comparisons for the analysis performed in 
this manuscript and have listed this in the limitations. All analyses were 
performed using SAS, version 9.4 (SAS, Inc., Cary, NC). 
 
Results 
Baseline Characteristics 
Figure 1 demonstrates the derivation of the final patient subset for 
analysis.   
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Of the 776 patients enrolled, 491 had both a final diagnosis of AHF and 
baseline/6 hour self-reported dyspnea; 93 reported ‘minimally improved’ and 7 
reported ‘minimally worse’ by 7-point Likert scale 6 hours after enrollment. Table 
1 shows the baseline characteristics of patients grouped by response on the 7-
point Likert.   
 
Table 1 – Baseline Characteristics Grouped by Patient-Reported ‘Minimally Worse’, ‘No Change’, 
or ‘Minimally Improved’ by 7-Point Likert Scale  Minimally 
Improved 
(n=93) No Change (n=68) Minimally Worse (n=7) 3-group P-value Minimally  Improved vs. No Change  
P-value 
Age, mean ± SD 68.3 ± 14.7 62.6 ± 
16.4 
62.0 ± 11.0 0.0575 0.0228 
Male gender, n (%) 52 (55.9%) 42 
(61.8%) 
4 (57.1%) 0.7931 0.5185 
White race, n (%) 74 (80.4%) 
(n=92) 
50 
(73.5%) 
4 (57.1%) 0.2148 0.3410 
LVEF, mean ± SD 39.7 ± 18.1 
(n=59) 
36.6 ± 
16.2 
(n=43) 
41.0 ± 13.5 
(n=3) 
0.6559 0.3813 
      
HISTORY, n (%)      
Heart Failure (n=91)   0.9491 0.8503 
   History of heart failure 69 (75.8%) 53 
(77.9%) 
6 (85.7%) . . 
   de novo heart failure 22 (24.2%) 15 
(22.1%) 
1 (14.3%) . . 
Coronary artery disease 50 (53.8%) 26 
(38.2%) 
3 (42.9%) 0.1484 0.0568 
Prior myocardial infarction 20 (21.5%) 18 
(26.5%) 
2 (28.6%) 0.6882 0.5734 
Valvular disease 14 (15.1%) 14 
(20.6%) 
0 (0.0%) 0.4040 0.4035 
Primary Cardiomyopathy 19 (20.4%) 18 
(26.5%) 
1 (14.3%) 0.6425 0.4487 
Prior percutaneous coronary 
intervention (PCI) 
10 (10.8%) 6 (8.8%) 3 (42.9%) 0.0555 0.7932 
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Prior coronary bypass grafts 11 (11.8%) 5 (7.4%) 0 (0.0%) 0.5658 0.4300 
Stroke (CVA) 8 (8.6%) 4 (5.9%) 0 (0.0%) 0.7419 0.5621 
Obesity 34 (36.6%) 12 
(17.6%) 
4 (57.1%) 0.0079 0.0129 
Peripheral vascular disease 7 (7.5%) 1 (1.5%) 0 (0.0%) 0.1975 0.1398 
Asthma/COPD 17 (18.3%) 8 (11.8%) 1 (14.3%) 0.5256 0.2808 
Diabetes - Insulin Dependent 15 (16.1%) 13 
(19.1%) 
2 (28.6%) 0.5667 0.6764 
Diabetes - Non-Insulin 
Dependent 
16 (17.2%) 13 
(19.1%) 
1 (14.3%) 0.9361 0.8364 
Renal insufficiency 26 (28.0%) 18 
(26.5%) 
2 (28.6%) 0.9545 0.8599 
Anemia (HG<12 g/dl) 18 (19.4%) 8 (11.8%) 0 (0.0%) 0.2920 0.2783 
Cancer history 6 (6.5%) 4 (5.9%) 1 (14.3%) 0.5097 1.0000 
Hypertension 66 (71.0%) 49 
(72.1%) 
5 (71.4%) 1.0000 1.0000 
      
VITAL SIGNS, mean ± SD      
Systolic Blood pressure (mm 
Hg) 
138.0 ± 
34.0 
132.9 ± 
32.5 
127.1 ± 
18.5 
0.4983 0.3417 
Diastolic Blood pressure (mm 
Hg) 
80.0 ± 17.4 76.6 ± 
20.8 
78.0 ± 15.2 0.5239 0.2607 
Heart rate (beats/min) 89.0 ± 25.3 89.4 ± 
21.5 
82.0 ± 17.9 0.7301 0.9191 
Respiratory rate (breaths/min) 22.3 ± 4.9 
(n=92) 
21.9 ± 4.9 
(n=66) 
21.3 ± 4.9 0.7767 0.5813 
Oxygen saturation (SpO2) 93.5 ± 4.9 
(n=90) 
95.6 ± 3.6 
(n=66) 
96.6 ± 2.4 0.0071 0.0030 
      
      
BASELINE MEDICATIONS, 
n(%) 
     
Beta-blockers 56 (60.2%) 41 
(60.3%) 
5 (71.4%) 0.9246 1.0000 
ACE Inhibitors 48 (51.6%) 41 
(60.3%) 
4 (57.1%) 0.5378 0.3359 
Angiotensin receptor blockers 10 (10.8%) 5 (7.4%) 1 (14.3%) 0.4968 0.5871 
Statins 33 (35.5%) 20 
(29.4%) 
0 (0.0%) 0.1241 0.4978 
Amlodipine/Felodipine (other 
dihydropyridine) 
11 (11.8%) 8 (11.8%) 0 (0.0%) 1.0000 1.0000 
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Nitrates 23 (24.7%) 10 
(14.7%) 
1 (14.3%) 0.3040 0.1661 
Aldosterone Antagonists 10 (10.8%) 15 
(22.1%) 
0 (0.0%) 0.0942 0.0765 
Diuretics 70 (75.3%) 50 
(73.5%) 
5 (71.4%) 0.9537 0.8556 
Cardiac Glycoside 20 (21.5%) 14 
(20.6%) 
0 (0.0%) 0.5866 1.0000 
Aspirin 37 (39.8%) 31 
(45.6%) 
2 (28.6%) 0.6020 0.5194 
Plavix 6 (6.5%) 9 (13.2%) 2 (28.6%) 0.0753 0.1743 
Coumadin 22 (23.7%) 16 
(23.5%) 
1 (14.3%) 1.0000 1.0000 
Other anti-coagulant 6 (6.5%) 4 (5.9%) 1 (14.3%) 0.5097 1.0000 
Pacemaker 7 (7.5%) 4 (5.9%) 2 (28.6%) 0.1591 0.7613 
Implantable cardioverter-
defribrillators (AICD) 
6 (6.5%) 5 (7.4%) 0 (0.0%) 1.0000 1.0000 
Cardiac resynchronization 
therapy (CRT) 
2 (2.2%) 0 (0.0%) 0 (0.0%) 0.5492 0.5090 
      
LABORATORY VALUES, 
mean ± SD 
     
BNP 1457.8 
±1434.3 
(n=33) 
1031.2 
±1217.2 
(n=26) 
620.5 ± 
419.5 
(n=4) 
0.3007 0.2309 
Serum sodium (mmol/L) 137.7 ± 4.6 
(n=88) 
137.8 ± 
5.3 
(n=66) 
139.9 ± 2.4 0.5238 0.8866 
Troponin I >0.04 (ng/mL) label 1.9 ± 4.6 
(n=29) 
2.2 ± 8.2 
(n=22) 
0.1 ± 0.0 
0.2 (n=2) 
0.8942 0.8631 
Creatinine 1.5 ± 0.7 
(n=89) 
1.7 ± 1.9 
(n=67) 
1.2 ± 0.3 0.6119 0.5202 
BUN (mg/dL) 35.4 ± 36.8 
(n=79) 
29.4 ± 
24.2 
(n=62) 
36.9 ± 32.7 
(n=6) 
0.5107 0.2420 
      
TREATMENT IN THE ED, n 
(%) 
     
Loop diuretic 89 (96.7%) 
(n=92) 
57 
(86.4%) 
(n=66) 
6 (85.7%) 0.0345 0.0290 
Vasodilator 24 (27.6%) 9 (14.1%) 0 (0.0%) 0.0547 0.0719 
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(n=87) (n=64) 
IV Inotrope and/or 
vasopressor 
11 (12.4%) 
(n=89) 
6 (9.2%) 
(n=65) 
1 (14.3%) 0.6803 0.6106 
      
DYSPNEA SCALES      
5 point Likert (upright; n (%)) (n=92) (n=67)  0.0067 0.0016 
   I am not SOB 3 (3.3%) 16 
(23.9%) 
1 (14.3%) .  
   Mildly SOB 36 (39.1%) 23 
(34.3%) 
2 (28.6%) .  
   Moderately SOB 29 (31.5%) 12 
(17.9%) 
2 (28.6%) .  
   Severely SOB 18 (19.6%) 11 
(16.4%) 
1 (14.3%) .  
   Very Severely SOB 6 (6.5%) 5 (7.5%) 1 (14.3%) .  
5 point Likert (supine, n(%)) (n=66) (n=48) (n=4) <.0001 <0.0001 
   I am not SOB 1 (1.5%) 13 
(27.1%) 
1 (25.0%) .  
   Mildly SOB 16 (24.2%) 7 (14.6%) 1 (25.0%) .  
   Moderately SOB 34 (51.5%) 25 
(52.1%) 
0 (0.0%) .  
   Severely SOB 15 (22.7%) 2 (4.2%) 2 (50.0%) .  
  Very Severely SOB 0 (0.0%) 1 (2.1%) 0 (0.0%) .  
Visual Analog Scale (upright), 
mean ± SD 
5.2 ± 2.7 
 
4.3 ± 3.0 4.4 ± 3.2 0.0961 0.0323 
Visual Analog Scale (supine), 
mean ± SD 
5.7 ± 2.2 
(n=67) 
4.0 ± 2.3 
(n=49) 
4.3 ± 3.0 
(n=4) 
0.0003 <0.0001  
 
Overall, very few patients (n=7) reported feeling ‘minimally worse’ at 6 
hours, limiting any comparisons. Characteristics were largely similar between 
those who reported ‘no change’ to those who reported ‘minimally improved.’  The 
largest differences were in baseline 5-point Likert responses. Those who 
reported ‘minimally improved’ were more likely to have worse dyspnea at 
baseline. (p=.0067) Other differences are as follows: More patients in the 
Page 15 of 29 
improved category were obese, had lower oxygen saturation at baseline, and 
had more loop diuretic use.(p < .05 for all) Supplemental Table 1 shows the 
characteristics for patients with any improvement or any worsening by 7-point 
Likert.  Similar to the ‘minimally improved or worse’ group, few patients (n=25) 
reported feeling worse at 6 hours. 
 
Anchor Scale Based Changes 
Table 2 shows the proportion of patients at 6 hours who reported 
‘minimally worse,’ ‘no change,’ and ‘minimally better’ scores by 7-point Likert 
relative to the categorized 6-hour change in the VAS and 5-point Likert scales in 
both the upright and supine positions.   
 
Table 2: Changes in Likert and VAS Relative to Anchor Scale at 6 hours 
 Change in 5-point Likert (Upright)  
(n=158; p-value=0.0005) 
7-Point Likert at 
6 hours Improved No Change Worse Total 
Minimally 
Improved 33 (37.5%) 51 (58.0%) 4 (4.5%) 88 
No Change 7 (10.9%) 51 (79.7%) 6 (9.4%) 64 
Minimally 
Worse 3 (50.0%) 2 (33.3%) 1 (16.7%) 6 
 Change in VAS (Upright)  
(n=165; p-value <0.0001) 
Minimally 
Improved 61 (65.6%) 20 (21.5%) 12 (12.9%) 93 
No Change 12 (18.5%) 42 (64.6%) 11 (16.9%) 65 
Minimally 
Worse 2 (28.6%) 0 (0.0%) 5 (71.4%) 7 
 Change in 5-point Likert (Supine)  
(n=112; p-value=0.0067) 
Minimally 
Improved 27 (42.9%) 34 (54.0%) 2 (3.2%) 63 
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No Change 8 (17.8%) 31 (68.9%) 6 (13.3%) 45 
Minimally 
Worse 0 (0.0%) 3 (75.0%) 1 (25.0%) 4 
 Change in VAS (Supine)  
(n=116; p-value <0.0001) 
Minimally 
Improved 48 (73.8%) 14 (21.5%) 3 (4.6%) 65 
No Change 16 (34.0%) 22 (46.8%) 9 (19.1%) 47 
Minimally 
Worse 0 (0.0%) 2 (50.0%) 2 (50.0%) 4   
 
Although there are significant differences between groups (p<0.01 for all), 
a sizable proportion of patients in every response category demonstrated 
discordant results. Patients who reported ‘minimally worse’ may have reported 
‘improved’ by an alternate scale. 
Table 3 shows the proportion of patients who reported any improvement, 
no change, and any worsening at 6 hours by 7-point Likert and the corresponding 
frequencies of patients’ response by 5-point and VAS.   
 
Table 3: Changes in Likert and VAS Relative to Any Improvement, No Change, or Any Worsening 
by Anchor Scale at 6 hours 
 
 5-point Likert (Upright) Change 
(n=467; p-value <0.0001, κ = 0.35, 95% CI (0.27-0.42)) 
7-Point Likert at 
6 hours Improved No Change Worse Total 
Improved 275 (72.6%) 94 (24.8%) 10 (2.6%) 379 
No Change 7 (10.9%) 51 (79.7%) 6 (9.4%) 64 
Worse 11 (45.8%) 7 (29.2%) 6 (25.0%) 24 
 5-point Likert (Supine) Change 
(n=282; p-value <0.0001. κ = 0.25, 95% CI (0.17-0.35)) 
Improved 142 (63.4%) 77 (34.4%) 5 (2.2%) 224 
No Change 8 (17.8%) 31 (68.9%) 6 (13.3%) 45 
Worse 3 (23.1%) 6 (46.2%) 4 (30.8%) 13 
 VAS (Upright) Change 
(n=485; p-value <0.0001, κ = 0.44, 95% CI (0.36-0.53)) 
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Improved 331 (83.8%) 44 (11.1%) 20 (5.1%) 395 
No Change 12 (18.5%) 42 (64.6%) 11 (16.9%) 65 
Worse 14 (56.0%) 0 (0.0%) 11 (44.0%) 25 
 VAS (Supine) Change 
(n=289; p value <0.0001, κ = 0.35, 95% CI (0.24-0.45)) 
Improved 187 (81.7%) 29 (12.7%) 13 (5.7%) 229 
No Change 16 (34.0%) 22 (46.8%) 9 (19.1%) 47 
Worse 4 (30.8%) 4 (30.8%) 5 (38.5%) 13 
 
 
For patients who reported any improvement by 7-point Likert, they were 
more likely to report feeling improved by alternate scales.  However, the results 
were inconsistent in regards to reporting ‘minimally worse’: many patients 
reported feeling improved by the alternate scale.  Overall, there was poor 
concordance between the scales. 
 
Minimally Clinical Important Difference 
The 6-hour change in 5-point Likert scale and VAS, relative to our criterion 
standard of the MCID — a one-category change in the 7-point Likert scale at 6 
hours — are reported in Table 4.   
Table 4: Patient Reported Changes in Dyspnea from Baseline to 6 hours on VAS or 5 Point Likert 
by Anchor Scale – Both One Category Change and Any Change  
 VAS Change (mm) UPRIGHT P-value 
VAS Change (mm) 
SUPINE P-value 
Minimally Improved 10.5 (1.6)  14.5 (2.0)  
No Change  0.3 (1.9)  4.6 (2.3)  
Minimally Worse -2.9 (5.7)  -12.5 (8.0)  
  <0.0001*  0.0002 
Any Improvement 24.7 (1.1)  20.2 (1.3)  
No Change 0.3 (2.7)  4.7 (2.8)  
Any Worsening 10.8 (4.3)  -0.8 (5.3)  
  <0.0001  <0.0001* 
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5-point Likert 
Change 
UPRIGHT 
P-value 
5-point Likert 
Change 
SUPINE 
P-value 
Minimally Improved 0.38(0.07)  0.48 (0.09)  
No Change  0.03 (0.09)  0.04 (0.10)  
Minimally Worse 0.67 (0.29)  -0.25 (0.34)  
  0.0045**  0.0021** 
Any Improvement 1.12 (0.05)  0.79 (0.05)  
No Change 0.03 (0.13)  0.04 (0.12)  
Any Worsening 0.67 (0.21)  -0.15 (0.22)  
  <0.0001  <0.0001* 
Results represent Least Square Means (Standard Errors) from One-Way Analysis of Variance 
Models on 
*No significant difference between No Change and Minimally Worse or Worse.  All other 
pairwise comparisons are significantly different.   
** Only the Improved vs. No change category is significantly different. No other pairwise 
comparisons are significantly different. 
 
 
Although a significant MCID for improvement was observed, the MCID for 
worsening was not statistically significant.  Changes in position seem to amplify 
the difference for improvement.  A 10.5mm (SE 20mm) change in VAS was the 
minimal clinical significant improvement difference in the upright position, but 
14.5mm (SE 20mm) was in the supine position.  
When patients who reported mild, moderate, or marked improvement or 
worsening were categorized into ‘any improvement, no change, or any 
worsening,’ the associated change in VAS was 24.7mm (SD 1.1) in the upright 
position and 20.2mm (SD 1.3) in the supine positions.  For the upright position 
only, a change of 10.8mm (SD 4.3) in VAS was associated with any worsening. 
(Table 4) In addition, Table 4 also reports the change relative to the 5-point Likert 
scale.  Although some significant differences were seen, given the 5-point scale 
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was an ordinal scale, no difference reached the 1-point threshold, with the 
exception of ‘any improvement.’ 
Of note, to account for the multiplicity of testing, we used the false 
discover rate (FDR) to determine which values were significant at FDR = 0.05.18  
Based on this criterion, all 16 p-values reported remain significant.   
  
Discussion 
 In this secondary analysis from the URGENT-Dyspnea registry, a minimal 
clinical important improvement in dyspnea was slightly greater than 10mm by 
VAS — in both the upright and supine positions at 6 hours after initial 
assessment.  Of note, the MCID for VAS in the supine position was greater 
(14.5mm) compared to VAS in the upright position (10.5mm).  We have 
previously reported the effect of positioning on dyspnea response, observing that 
supine positioning more robustly captures the symptom.  8No significant MCID in 
terms of worsening was observed, however.  This was driven primarily by the 
lack of patients who felt worse.   
 We did not find the MCID for the 5-point Likert scale however, irrespective 
of position.  Although easier to administer, the Likert scale may measure 
dyspnea differently8 10 Alternatively, the categorical responses may not 
discriminate dyspnea sufficiently.  We, along with others, have reported 
differences between the scales despite the same population.7,8 
 To the best of our knowledge, the only other study to explore the MCID in 
AHF was conducted in ED patients by Ander et.al.15 Using a similar methodology 
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of a 1-point difference in a 5-point VAS as the criterion standard for the MCID, 
Ander et.al. enrolled 74 patients from a single center, and found 21.1mm to be 
the MCID for both a ‘little less difficulty breathing’ and a ‘little more difficulty 
breathing.’15 Patients were assessed every 20 minutes to a maximum of 2 hours, 
unlike our study, which did a single assessment at 6 hours.  Differences between 
this study and our analysis may have been driven by the frequency of 
assessments, the short timeframe over which to assess the MCID, geographical 
variation, or baseline differences in dyspnea severity.  We had previously shown 
that dyspnea improves rapidly within the first 6 hours of therapy.8 
 This method of utilizing one scale to determine the MCID in another scale 
— anchor based method — has been previously used in AHF15 as well as pain 
scales.16 In fact, significant differences in VAS pain perception, 13mm on a 
100mm scale,17 are remarkably similar to our findings. This further supports the 
importance of our findings and supports patient reported dyspnea as an 
appropriate physiologic endpoint in AHF studies, commensurate to that of the 
experience of pain. Although attempts to correlate a subjective response with 
objective criteria are understandable,11 the patients’ response continues to be an 
important perspective.  For a symptom such as dyspnea, the patients’ response 
may be the only valid one.19 However, the MCID may differ based on the 
phenotype of AHF studied, the timing of assessment, and the setting in which it is 
assessed.19 Thus, continued work is needed to better understand the MCID in 
AHF.  
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 Unlike the MCID, when ‘any worsening’ or ‘any improvement’ was used as 
the criterion standard, a much greater change in VAS was noted.  Interestingly, 
‘any worsening’ was associated with improvement by VAS.  This finding was also 
observed with the 5-point Likert.  For both scales, this paradoxical finding was 
attenuated by position.  Although there was still improvement, a smaller 
proportion reported improvement in supine vs. upright position.  Overall, the 
numbers of patients who reported worse dyspnea was small.  Another related 
finding was the lack of concordance between the scales.  As discussed in a prior 
analysis,10 such discordance suggests each scale may capture different aspects 
of this subjective symptom. 
 Enthusiasm for dyspnea as an endpoint has waned in clinical trials.12 In 
part, this is due to the difficulty of achieving a substantial effect over usual 
therapy.  However, failure to achieve a differential effect with novel therapies 
does not mitigate its importance to patients. Additionally, failure to identify a 
MCID may have also contributed to the waning interest in dyspnea as a trial 
endpoint.  In other fields, such as asthma, where dyspnea is also a predominant 
symptom, multiple scales and MCID’s are well established.  As a result, dyspnea 
remains a key endpoint.20 Alternatively, in COPD, although MCID for dyspnea in 
the chronic setting exist, there is actually no MCID for COPD exacerbations.21 
Future work to confirm our findings are needed. 
  
Limitations 
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 Our study has several limitations.  As a secondary analysis, unmeasured 
confounders may significantly impact our findings.  The total number of patients 
who reported minimal improvement or worsening was also small.  Larger 
numbers may have yielded different results or more narrow confidence intervals. 
However, our study is one of the larger studies conducted in the ED setting to 
examine the MCID.  In addition, other MCID’s have been driven largely by 
improvement.22 Our study also uses only a single anchor based method to 
determine the MCID.  Although the anchor is well established in AHF clinical 
trials, 13 we did not specifically address other key domains, such as construct and 
content validity.  More frequent measurements may have also yielded different 
results.  We also did not control for multiple comparisons, as we considered each 
comparison to be sufficiently unique so that family-wise type I error is not 
particularly relevant.   
 
Conclusion 
Dyspnea is the most common symptom in patients presenting with AHF.  A 10.5 
mm change is the MCID for a 6-hour dyspnea improvement in ED patients with 
AHF. As a patient reported outcome, a better understanding of the MCID may 
inform future studies targeting this symptom. 
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Figure Legends: 
Figure 1: Study Patient Flow 
AHF = Acute Heart Failure 
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Supplemental Table 1.  Baseline Characteristics Grouped by Patient Reported ‘Any 
Improvement’, ‘No Change’ or ‘Any Worsening’ by 7-Point Likert 
  Improved 
(n=398) No Change (n=68) Worse (n=25) 3-group P-value Minimally  Improved vs. No 
Change  
P-value 
Age, mean ± SD 69.1 ± 14.3 62.6 ± 16.4 67.5 ± 
13.9 
0.0034 0.0008 
Male gender, n (%) 226 (56.8%) 42 (61.8%) 12 (48.0%) 0.4662 0.5075 
White race, n (%) 330 (83.1%) 
(n=397) 
50 (73.5%) 21 (84.0%) 0.1766 0.0634 
LVEF, mean ± SD 40.6 ± 16.9 
(n=202) 
36.6 ± 16.2 
(n=43) 
42.3 ± 
17.8 
(n=7) 
0.3404 0.1550 
      
HISTORY, n (%)      
Heart Failure (n=386)   0.0139 0.0043 
   History of heart failure 231 (59.8%) 53 (77.9%) 16 (64.0%) . . 
   de novo heart failure 155 (40.2%) 15 (22.1%) 9 (36.0%) . . 
Coronary artery disease 175 (44.0%) 26 (38.2%) 8 (32.0%) 0.3911 0.4275 
Prior myocardial infarction 101 (25.4%) 18 (26.5%) 5 (20.0%) 0.8553 0.8806 
Valvular disease 59 (14.8%) 14 (20.6%) 5 (20.0%) 0.3579 0.2772 
Primary Cardiomyopathy 46 (11.6%) 18 (26.5%) 2 (8.0%) 0.0045 0.0021 
Prior percutaneous coronary 
intervention (PCI) 
42 (10.6%) 6 (8.8%) 4 (16.0%) 0.5328 0.8299 
Prior coronary bypass grafts 33 (8.3%) 5 (7.4%) 1 (4.0%) 0.9443 1.0000 
Stroke (CVA) 30 (7.5%) 4 (5.9%) 0 (0.0%) 0.4556 0.8028 
Obesity 106 (26.6%) 12 (17.6%) 5 (20.0%) 0.2549 0.1322 
Peripheral vascular disease 41 (10.3%) 1 (1.5%) 0 (0.0%) 0.0116 0.0191 
Asthma/COPD 73 (18.3%) 8 (11.8%) 5 (20.0%) 0.3885 0.2265 
Diabetes - Insulin Dependent 61 (15.3%) 13 (19.1%) 4 (16.0%) 0.7051 0.4721 
Diabetes - Non-Insulin Dependent 82 (20.6%) 13 (19.1%) 4 (16.0%) 0.9243 0.8714 
Renal insufficiency 107 (26.9%) 18 (26.5%) 3 (12.0%) 0.2779 1.0000 
Anemia (HG<12 g/dl) 55 (13.8%) 8 (11.8%) 5 (20.0%) 0.5635 0.8477 
Cancer history 25 (6.3%) 4 (5.9%) 2 (8.0%) 0.8064 1.0000 
Hypertension 304 (76.4%) 49 (72.1%) 16 (64.0%) 0.2917 0.4462 
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VITAL SIGNS, mean ± SD      
Systolic Blood pressure (mm Hg) 146.2 ± 34.4 132.9 ± 
32.5 
132.8 ± 
26.4 
0.0032 0.0032 
Diastolic Blood pressure (mm Hg) 82.7 ± 19.6 
(n=397) 
76.6 ± 20.8 74.4 ± 
17.4 
0.0127 0.0204 
Heart rate (beats/min) 91.8 ± 24.3 89.4 ± 21.5 84.1 ± 
13.3 
0.2307 0.4430 
Respiratory rate (breaths/min) 23.1 ± 6.3 
(n=390) 
21.9 ± 4.9 
(n=66) 
21.5 ± 6.3 
(n=24) 
0.1971 0.0841 
Oxygen saturation (SpO2) 92.7 ± 5.8 
(n=354) 
95.6 ± 3.6 
(n=66) 
92.7 ± 8.0 
(n=21) 
0.0008 <0.0001 
      
      
BASELINE MEDICATIONS, n(%)      
Beta-blockers 200 (50.3%) 41 (60.3%) 15 (60.0%) 0.2271 0.1487 
ACE Inhibitors 181 (45.5%) 41 (60.3%) 10 (40.0%) 0.0610 0.0258 
Angiotensin receptor blockers 52 (13.1%) 5 (7.4%) 4 (16.0%) 0.3455 0.2310 
Statins 108 (27.1%) 20 (29.4%) 6 (24.0%) 0.8798 0.7688 
Amlodipine/Felodipine (other 
dihydropyridine) 
56 (14.1%) 8 (11.8%) 4 (16.0%) 0.8378 0.7059 
Nitrates 84 (21.1%) 10 (14.7%) 3 (12.0%) 0.3598 0.2555 
Aldosterone Antagonists 37 (9.3%) 15 (22.1%) 3 (12.0%) 0.0119 0.0054 
Diuretics 252 (63.3%) 50 (73.5%) 17 (68.0%) 0.2548 0.1302 
Cardiac Glycoside 75 (18.8%) 14 (20.6%) 2 (8.0%) 0.3727 0.7394 
Aspirin 137 (34.4%) 31 (45.6%) 8 (32.0%) 0.1919 0.1004 
Plavix 34 (8.5%) 9 (13.2%) 2 (8.0%) 0.4573 0.2539 
Coumadin 64 (16.1%) 16 (23.5%) 2 (8.0%) 0.1708 0.1624 
Other anti-coagulant 43 (10.8%) 4 (5.9%) 4 (16.0%) 0.3092 0.2776 
Pacemaker 24 (6.0%) 4 (5.9%) 2 (8.0%) 0.7994 1.0000 
Implantable cardioverter-
defribrillators (AICD) 
16 (4.0%) 5 (7.4%) 2 (8.0%) 0.2322 0.2113 
Cardiac resynchronization therapy 
(CRT) 
2 (0.5%) 0 (0.0%) 0 (0.0%) 1.0000 1.0000 
      
LABORATORY VALUES, mean ± 
SD 
     
BNP 1374.9 
±1243.5 
(n=94) 
1031.2 
±1217.2 
(n=26) 
867.5 ± 
873.6 
(n=6) 
0.3176 0.2128 
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Serum sodium (mmol/L) 137.9 ± 4.4 
(n=386) 
137.8 ± 5.3 
(n=66) 
137.8 ± 
3.8 
0.9743 0.8565 
Troponin I >0.04 (ng/mL) label 5.8 ± 12.6 
(n=159) 
2.2 ± 8.2 
(n=22) 
7.5 ± 13.4 
(n=6) 
0.4120 0.0899 
Creatinine 1.5 ± 1.3 
(n=386) 
1.7 ± 1.9 
(n=67) 
1.2 ± 0.5 
(n=24) 
0.3456 0.6014 
BUN (mg/dL) 29.6 ± 25.3 
(n=360) 
29.4 ± 24.2 
(n=62) 
27.4 ± 
19.9 
(n=21) 
0.9265 0.9549 
      
TREATMENT IN THE ED, n (%)      
Loop diuretic 337 (84.9%) 
(n=397) 
57 (86.4%) 
(n=66) 
19 (76.0%) 0.4196 0.8535 
Vasodilator 112 (30.0%) 
(n=373) 
9 (14.1%) 
(n=64) 
3 (13.0%) 
(n=23) 
0.0078 0.0096 
IV Inotrope and/or vasopressor 30 (8.1%) 
(n=370) 
6 (9.2%) 
(n=65) 
4 (16.7%) 
(n=24) 
0.3071 0.8066 
      
DYSPNEA SCALES      
5 point Likert (upright; n (%)) (n=394) (n=67)  <.0001 <.0001 
   I am not SOB 16 (4.1%) 16 (23.9%) 2 (8.0%) . . 
   Mildly SOB 95 (24.1%) 23 (34.3%) 6 (24.0%) . . 
   Moderately SOB 134 (34.0%) 12 (17.9%) 7 (28.0%) . . 
   Severely SOB 83 (21.1%) 11 (16.4%) 8 (32.0%) . . 
   Very Severely SOB 66 (16.8%) 5 (7.5%) 2 (8.0%) . . 
5 point Likert (supine, n(%)) (n=235) (n=48) (n=14) <.0001 <.0001 
   I am not SOB 11 (4.7%) 13 (27.1%) 1 (7.1%) . . 
   Mildly SOB 43 (18.3%) 7 (14.6%) 7 (50.0%) . . 
   Moderately SOB 120 (51.1%) 25 (52.1%) 0 (0.0%) . . 
   Severely SOB 55 (23.4%) 2 (4.2%) 6 (42.9%) . . 
  Very Severely SOB 6 (2.6%) 1 (2.1%) 0 (0.0%) . . 
Visual Analog Scale (upright), mean 
± SD 
5.8 ± 2.6 4.3 ± 3.0 5.6 ± 2.7 <.0001 <.0001 
Visual Analog Scale (supine), mean 
± SD 
5.6 ± 2.2 
(n=237) 
4.0 ± 2.3 
(n=49) 
5.1 ± 3.0 
(n=14) 
<.0001 <.0001 
 
 
